Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2019

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Pharma intelligence for marketing agencies

Gain insight into the pharmaceutical market landscape – we’ll help you communicate complex ideas clearly and develop customer-centric propositions.

Supporting market access strategy

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. As a marketer, you have to engage with multiple audiences across a variety of channels and to communicate complex information simply and persuasively.

We give you the means to identify future innovation and new market opportunities, develop customer-centric propositions, and keep a close eye on competitors. We can also help with branding, multi-channel communication and more.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our pharma intelligence will help you build a complete picture of the market and get access to past, current and future trends and analysis.

How it helps

You’ll get cutting-edge insights on the size and shape of markets, competitive threats, actionable customer perceptions and industry innovations.

Our accurate, reliable intelligence will help you:

Access in-depth knowledge from drug discovery to market access
Acquire a comprehensive understanding of the global pharma market
Get in-depth coverage of the entire pharmaceutical value-chain

Our unique strengths

Understand your clients’ world

Gain comprehensive knowledge of the global pharma market with our complete coverage.

Think ahead

Respond to market events, identify opportunities and anticipate changes by tracking updates impacting the pharmaceutical industry.

Deliver tailored solutions

Use our data and insight to create solutions to suit your clients’ needs.

Benefit from a dedicated service

Our services come with dedicated client service and analyst support.

View more
View Less

Relevant products

Awareness

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Effective reporting

HBW Insight: Health, Beauty and Wellness

The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.

Key benefits:

Get a global view
Be the first to know
Go beyond the news

Generics Bulletin

A well-respected and trusted industry source for the last 15 years, Generics Bulletin from Informa Pharma Intelligence provides in-depth news and analysis on issues that matter most to businesses across the generics, biosimilars and value-added medicines industries.

Key benefits:

Ask-the-Analyst™ Service
A powerful online platform
In-depth content coverage

View all content

Datamonitor Healthcare

Reimbursement and Payer Management of Immune Checkpoint Inhibitors

21 Aug 2019

As immune checkpoint inhibitors continue to gain approvals in expanded patient populations, payers express concern surrounding the potential budget impact of the drug class. Considering the high costs of these treatments in comparison to standard chemotherapy, HTA and reimbursement agencies stress the requirement for solid survival data and highlight that price will be a major factor during negotiations

Topic Drug review

Single report
Datamonitor Healthcare

NASH Disease Coverage Extract

16 Aug 2019

Datamonitor Healthcare recently surveyed 60 gastroenterologists in the US and five major EU markets after the approval of the first disease-specific therapies for the treatment of non-alcoholic steatohepatitis (NASH). The market for these treatments will exceed $21bn in 2027.

Topic Drug development landscape Diseases

Single report
Generics Bulletin

Hikma Snaps Up Insys Sprays As Part Of US Drive Towards Differentiation

By Aidan Fry 15 Aug 2019

By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.

Topic Business strategies

View article
Scrip

An AdComm After All: Amarin's Vascepa Labeling Update Now Delayed By FDA

By Mandy Jackson 15 Aug 2019

The US FDA informed the company it will convene an advisory committee meeting to review the REDUCE-IT sNDA for the proprietary fish oil pill, delaying the approval by at least three months and surprising investors.

Topic FDA Drug approval

View article
Scrip

Taltz Tops Tremfya In Head-To-Head Psoriasis Study On Complete Skin Clearance

By Jessica Merrill 15 Aug 2019

Lilly's IL-17A inhibitor ixekizumab outperformed J&J's IL-23 inhibitor guselkumab on achieving complete skin clearance in moderate-to-severe psoriasis patients at 12 weeks in a head-to-head trial.

Topic Clinical trials

View article
Pink Sheet

Novartis' Zolgensma Had Manipulated Data In Application, US FDA Says

By Derrick Gingery 14 Aug 2019

Gene therapy should remain on the market, FDA says, but Novartis could face civil or criminal penalties. Firm knew of problems before approval.

Topic FDA Company analysis

View article
Generics Bulletin

Chirag Patel And Chintu Patel Return As Co-CEOs Of Amneal

By David Wallace 14 Aug 2019

Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.

Topic Company analysis

View article
Scrip

Oncology Market Leaders Maintain Their Upper Hand

By Jessica Merrill 14 Aug 2019

Drugs like Ibrance and Lynparza show that in the cancer market, it can be hard for new entrants to catch early standouts.

Topic Drug development landscape Drug review

View article
Scrip

The Chinese Pharma Market: Insights in turbulent times

12 Aug 2019

With the continuation of the US-China trade standoff, the rapid increase in R&D costs and a gruelling centralized bidding process, foreign pharma firms have a lot on their plates in China. Gain insight on these key challenges through this Scrip article pack

Topic Business strategies

Single report
Pink Sheet

The Stakes Are High So Get It Right: CHMP Oral Explanations & FDA AdComs

By Neena Brizmohun 09 Aug 2019

The stakes are extremely high for companies called before EU or US regulators and scientific experts to answer queries about their new drug applications at the later stages of the review process. How they perform is critical. Consultant Kate Dion has a raft of helpful tips for companies facing this daunting situation. Neena Brizmohun reports.

Topic Drug approval

View article
Pink Sheet

FTC Wades Into ‘Rebate Walls’ And Biosimilar Access With Remicade Investigation

By Cathy Kelly 09 Aug 2019

Investigation may help define when rebate arrangements seeking to protect a brand against biosimilar competition are anticompetitive.

Topic Policy and regulation

View article
Generics Bulletin

Reddy's Will Look For Acquisitions Under New CEO Israeli

By Aidan Fry 09 Aug 2019

With Erez Israeli set to step up from COO to CEO, Dr Reddy’s is looking to leverage its lack of debt and strong cash flow in the mergers and acquisitions arena.

Topic Business strategies

View article
HBW Insight

Japan's New Rx-To-OTC Procedure Exacerbating Switch Blockage Says JSMI

By David Ridley 07 Aug 2019

Japan's new Rx-to-OTC switch procedure has exacerbated a "switch lag" compared with developed countries, says Japan Self-Medication Industry senior adviser Toshi Tominaga in an exclusive interview with HBW Insight. Tominaga proposes improvements such as self-care education for consumers and drug usage advice included by firms in switch applications to help balance the risk-benefit decisions of expert judges.

Topic Policy and regulation

View article
Scrip

Love From Shanghai: Upjohn Started Here But Will It Stay Post-Mylan?

By Brian Yang 05 Aug 2019

Opened with a big splash just two months ago in a brand new headquarters in Shanghai, Pfizer's Upjohn established products subsidiary is now merging with Mylan to create the world's largest generics group, stirring up local concerns that the focus could shift from China back to the US.

Topic Company analysis Business strategies

View article
Scrip

At Pfizer, A Split A Decade In The Making

By Jessica Merrill 05 Aug 2019

Pfizer's ambitious plans to spin out its Upjohn branded and generics business will result in a smaller, innovation-focused pharma. The decision comes after nine years of back-and-forth about whether the move would unlock value.

Topic BioPharmaceutical Company analysis

View article

Latest headlines

Scrip

23 Aug 2019

DREAMM-2 Put GSK’s BCMA Drug In Pole Position In Multiple Myeloma

Link
Pink Sheet

23 Aug 2019

Pink Sheet Podcast: Golodirsen CRL, Trump's Appeal Of DTC Ad Ruling, Pharmas' Statement Of Purpose'

Link
Pink Sheet

23 Aug 2019

Germany Remains In The Dark On UPC Implementation

Link
Scrip

23 Aug 2019

Lupin Rationalizes Japan Operations, Sheds Injectables Business

Link
Scrip

23 Aug 2019

Deal Watch: Themis Leverages Measles Vector Platform In Collaboration With Merck & Co.

Link
Pink Sheet

23 Aug 2019

Keeping Track: US FDA Greenlights Two More Novel Drugs, But Smacks Down Golodirsen

Link
Scrip

23 Aug 2019

Finance Watch: Five More Biopharmas Enter US Queue Even As IPO Returns Dip

Link
Pink Sheet

23 Aug 2019

NICE Says Initial No To Epidyolex In England, But GW Pharma Remains Upbeat

Link
Pink Sheet

23 Aug 2019

Behind-The-Scenes Battles As Opioid MDL Jury Trial Nears

Link
Pink Sheet

23 Aug 2019

Opioid Litigation Pushes American Pain Society Into Bankruptcy

Link
Pink Sheet

23 Aug 2019

Recent And Upcoming FDA Advisory Committee Meetings

Link
Pink Sheet

23 Aug 2019

UK’s No-Deal Brexit Plans For SPC Waiver Could Reduce IP Rights, Warns BIA

Link
Pink Sheet

23 Aug 2019

£197m Payments Made Under New UK Pricing Scheme But Access Promises Still To Materialize

Link
Scrip

22 Aug 2019

Longer Intervals OK With ViiV's Injectable Anti-HIV Regimen

Link
Pink Sheet

22 Aug 2019

Enforcing A Belated Chemistry Lesson – The Nitrosamines In Sartans Saga

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Pharma intelligence for marketing agencies

Supporting market access strategy

Our unique strengths

Understand your clients’ world

Think ahead

Deliver tailored solutions

Benefit from a dedicated service

Relevant products

Below are the Product List

Awareness

HBW Insight: Health, Beauty and Wellness

Generics Bulletin

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Pharma Report Store